Video: Immunotherapy Tie-Ups Key For Future Of ADC Space
This article was originally published in Scrip
Executive Summary
Richard Onyett, business development director of ADC Therapeutics, chats to Mike Ward, global director of content for Informa Pharma Insights, about developments in the area of antibody drug conjugates (ADCs), a field that seems to have been overshadowed by the recent immunotherapy boom. They discuss how the two fields will combine in the future in oncology and where derailed ADC companies went wrong.